The latest domestic price of rubicatin/rubitidine in 2025

Lurbinectedin is a new type of RNA polymerase II inhibitor, mainly used to treat small cell lung cancer (SCLC), especially for patients who have relapsed after receiving platinum-based chemotherapy. Such patients usually have a poor prognosis, and the mechanism of rubitidine can effectively block the DNA transcription process of tumor cells and induce cell apoptosis, so it shows unique advantages in second-line treatment. At present, the drug has obtained marketing authorization in Europe and the United States, and has entered the clinical guide lists of many countries. It is worth noting that rubitidine is being used to study other difficult-to-treat tumor indications, including ovarian cancer and breast cancer, to broaden its treatment scope.

In terms of price, as an original and innovative drug, rubitidine has a relatively high cost. Taking the currently marketed version in China as an example, rubitidine for injection (specification4mg) sells for about more than 20,000 yuan per box. It has not yet been included in the national medical insurance catalog, and patients need to pay the full amount out of their own pocket. In Hong Kong and Macao, the original drug has also been launched, and the price remains around 20,000 yuan, with slight fluctuations depending on exchange rates and channels. In the international market, the US version of rubitidine sells for up to RMB 90,000 per box, while the market price in Singapore is about RMB 30,000. This difference is mainly due to differences in pricing mechanisms, reimbursement systems and distribution costs in various countries.

Currently, there are no generic drugs of rubitidine on the market globally, indicating that its patent protection system is still intact and there will be less market competition pressure in the short term. However, as China's market demand grows and policies promote the substitution of generic drugs, the emergence of domestic versions in the future may significantly reduce its cost of use.

Overall, although the price of rubitidine is high, its potential value in the treatment of refractory tumors and clinical demand support its market existence. If it can be included in medical insurance or enter the market through domestic generic drugs, the price reduction space is worth looking forward to.

Reference materials:https://www.zepzelca.com/